Repligen (RGEN) AI Stock Analysis

• Market Cap: $7.09B
• Dividend Yield: N/A
• Average Volume (3M): 756.92K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.31
• Revenue Growth: 8.73%
• EPS Growth: -245.82%
• Country: US
• Employees: 1,778
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 0.37
• Shares Outstanding: 56,257,618
• 10 Day Avg. Volume: 858,692
• 30 Day Avg. Volume: 756,925
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.99
• Enterprise Value/Revenue: 10.85
• Enterprise Value/Gross Profit: 25.40
• Enterprise Value/Ebitda: 58.91
• 1Y Price Target: $178.08
• Price Target Upside: 41.40% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 14

• Rating: 56 Neutral
• Price Target: $123.00 ▼(-2.33% Downside)

Repligen's overall stock score is primarily influenced by its mixed financial performance and strong earnings call guidance. While the company shows strong organic growth and strategic optimism, profitability challenges and valuation concerns weigh on the score. Technical analysis indicates a bearish trend, further impacting the overall assessment.

Positive Factors

Organic Revenue Growth

The strong organic revenue growth indicates robust demand for Repligen's products, suggesting a solid market position and potential for continued expansion in the biopharmaceutical sector.

Chromatography Segment Success

The significant growth in the Chromatography segment highlights Repligen's competitive advantage and innovation in this area, which is crucial for sustaining long-term revenue growth.

Strong Financial Guidance

Raising revenue guidance reflects management's confidence in future performance and strategic initiatives, which can enhance investor confidence and support long-term growth.

Negative Factors

Profitability Challenges

Negative profitability metrics indicate potential issues with cost management or pricing strategy, which could hinder Repligen's ability to generate sustainable profits over time.

Gene Therapy Revenue Headwind

The slowdown in gene therapy revenue growth poses a risk to Repligen's diversification strategy, potentially impacting overall revenue growth if not addressed.

Gross Margin Pressure

Flat gross margins suggest challenges in maintaining cost efficiency, which could affect Repligen's ability to improve profitability and financial health in the long term.

Repligen Business Overview & Revenue Model

Company Description

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and SpectraFlo dynamic dialysis systems; and ProConnex single-use hollow fiber. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. Repligen Corporation was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

How the Company Makes Money

Repligen generates revenue primarily through the sale of its bioprocessing products and technologies. Key revenue streams include the sale of chromatography resins, filtration products, and other consumables used in biomanufacturing processes. The company also derives income from its services related to product development and customer support. Significant partnerships with leading biopharmaceutical companies enhance its market presence and contribute to its earnings by ensuring consistent demand for its products. Additionally, Repligen's focus on innovation and expansion into new markets helps to drive growth and diversify its revenue base.

Repligen Financial Statement Overview

Summary

Repligen's financial performance is mixed, with strong balance sheet indicators like low leverage and a healthy equity ratio. However, profitability challenges are evident with negative net income and EBIT margins, despite positive operational cash flow.

Income Statement

Repligen's revenue shows a marginal growth from the previous year, but has declined from 2022. The gross profit margin for TTM is approximately 54.88%, indicating decent cost management. However, the company is experiencing negative net income and EBIT margins, highlighting profitability challenges. The EBITDA margin is positive at 13.80%, suggesting some operational efficiency.

Balance Sheet

The company's balance sheet is relatively strong with a debt-to-equity ratio of approximately 0.34, indicating low leverage. The equity ratio is around 69.60%, reflecting a healthy balance of equity financing. However, the return on equity is negative due to net losses, which is a concern for investors seeking returns.

Cash Flow

Repligen's cash flow statement shows a decrease in free cash flow compared to the annual report, with a negative free cash flow growth rate. The operating cash flow to net income ratio is negative due to the net loss, but operating cash flow remains positive, which indicates underlying operational strength despite profitability concerns.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	645.66M	634.44M	632.36M	801.54M	670.53M	366.26M
Gross Profit	275.86M	274.64M	308.83M	455.71M	391.25M	209.63M
EBITDA	118.93M	82.10M	127.77M	246.93M	211.56M	101.62M
Net Income	-25.37M	-25.51M	35.60M	185.96M	128.29M	59.93M
Balance Sheet
Total Assets	2.85B	2.83B	2.83B	2.53B	2.36B	1.90B
Cash, Cash Equivalents and Short-Term Investments	697.23M	757.36M	751.32M	623.76M	603.81M	717.29M
Total Debt	683.70M	686.25M	711.80M	422.96M	366.05M	275.42M
Total Liabilities	866.66M	856.95M	866.34M	620.90M	608.29M	373.74M
Stockholders Equity	1.99B	1.97B	1.96B	1.91B	1.75B	1.53B
Cash Flow
Free Cash Flow	117.60M	142.49M	74.93M	38.74M	47.74M	36.28M
Operating Cash Flow	145.69M	175.39M	113.92M	172.08M	119.02M	62.63M
Investing Cash Flow	-152.13M	-86.38M	-123.28M	-233.24M	-221.17M	-201.38M
Financing Cash Flow	-78.96M	-82.90M	248.96M	-13.34M	961.00K	305.92M

Repligen Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 125.94
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RGEN, the sentiment is Positive. The current price of 125.94 is above the 20-day moving average (MA) of 120.26, above the 50-day MA of 119.85, and below the 200-day MA of 135.69, indicating a neutral trend. The MACD of 0.38 indicates Negative momentum. The RSI at 57.20 is Neutral, neither overbought nor oversold. The STOCH value of 81.87 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for RGEN.

Repligen Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MMSI	79 Outperform	4.95B	42.47	8.01%	―	10.14%	0.04%
TFX	73 Outperform	5.43B	28.87	1.63%	1.11%	1.11%	-23.73%
ATR	72 Outperform	8.74B	23.19	14.50%	1.36%	1.51%	21.70%
STVN	66 Neutral	7.35B	50.06	9.63%	0.23%	5.95%	7.73%
BLCO	57 Neutral	5.40B	-19.72	-6.23%	―	8.81%	40.43%
RGEN	56 Neutral	$7.09B	―	-0.68%	―	8.73%	-245.82%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Repligen Corporate Events

Repligen Appoints Violetta Hughes as Chief Accounting Officer

On September 2, 2025, Repligen Corporation announced the appointment of Violetta Hughes as the new Chief Accounting Officer, effective September 1, 2025. This strategic move aims to enhance the company’s financial reporting infrastructure and compliance with the Sarbanes–Oxley Act. Ms. Hughes, a seasoned finance executive with over 25 years of experience, will replace Jason K. Garland, who will continue as the Chief Financial Officer focusing on corporate strategy and growth. Her extensive background in financial governance and SOX compliance is expected to bring significant improvements to Repligen’s financial transparency and strategic decision-making processes.